V Barban

Summary

Affiliation: Sanofi Pasteur

Publications

  1. doi request reprint Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses
    Veronique Barban
    Research Department, Sanofi Pasteur Campus Merieux, 1541 Avenue Marcel Merieux, 69680 Marcy l Etoile, France
    Virology 429:91-8. 2012
  2. ncbi request reprint High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production
    V Barban
    Research Department, Sanofi Pasteur, Marcy l Etoile, France
    Vaccine 25:2941-50. 2007
  3. doi request reprint Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines
    N Mantel
    Microbiology Research Department, Sanofi Pasteur, 1541 Avenue Marcel Merieux, 69280 Marcy l Etoile, France
    J Virol Methods 151:40-6. 2008
  4. doi request reprint Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses
    N Mantel
    Preclinical Research Department, Sanofi Pasteur, France
    Vaccine 29:6629-35. 2011
  5. ncbi request reprint Identification of a human epitope in hepatitis C virus (HCV) core protein using a molecularly cloned antibody repertoire from a non-symptomatic, anti-HCV-positive patient
    V Barban
    Research Department, Pasteur Merieux Connaught, 69290 Marcy l Etoile, France
    J Gen Virol 81:461-9. 2000

Collaborators

Detail Information

Publications5

  1. doi request reprint Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses
    Veronique Barban
    Research Department, Sanofi Pasteur Campus Merieux, 1541 Avenue Marcel Merieux, 69680 Marcy l Etoile, France
    Virology 429:91-8. 2012
    ..These data indicate that antibodies elicited after immunization with this dengue vaccine candidate should widely protect against infection with contemporary DENV lineages circulating in endemic countries...
  2. ncbi request reprint High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production
    V Barban
    Research Department, Sanofi Pasteur, Marcy l Etoile, France
    Vaccine 25:2941-50. 2007
    ..Taken together, these data demonstrate the genetic stability of the strain at mass production level over a period of 12 years and reinforce the generally admitted idea of the safety of YF17D-based vaccines...
  3. doi request reprint Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines
    N Mantel
    Microbiology Research Department, Sanofi Pasteur, 1541 Avenue Marcel Merieux, 69280 Marcy l Etoile, France
    J Virol Methods 151:40-6. 2008
    ..Reproducibility of RNA extraction was ensured by automation of the process (yield>or=50%), and infectious virus was isolated in >or=80% of PCR-positive sera from immune monkeys...
  4. doi request reprint Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses
    N Mantel
    Preclinical Research Department, Sanofi Pasteur, France
    Vaccine 29:6629-35. 2011
    ..Combined with the data reported here about the genetic stability of the vaccine strains, the probability of in vivo emergence of mutant viruses appears very low...
  5. ncbi request reprint Identification of a human epitope in hepatitis C virus (HCV) core protein using a molecularly cloned antibody repertoire from a non-symptomatic, anti-HCV-positive patient
    V Barban
    Research Department, Pasteur Merieux Connaught, 69290 Marcy l Etoile, France
    J Gen Virol 81:461-9. 2000
    ..However, we confirmed the specificity of these peptides by competition experiments with sFabC14...